The constant threat of recurrence feels like the proverbial sword of Damocles — always present, always waiting. If my cancer does return, the now-inert metal seeds scattered through my prostate and ...

Androgen Deprivation Therapy (ADT) ADT, says Dr. Armstrong, was the subject of the very first Nobel Prize in Medicine related to cancer, won by Charles B. Huggins in 1966.

Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...

Androgen Deprivation Therapy (ADT) ADT, says Dr. Armstrong, was the subject of the very first Nobel Prize in Medicine related to cancer, won by Charles B. Huggins in 1966. [ 2 ] ...

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE ...

Among patients with metastatic hormone-sensitive prostate cancer, the treatment combination of Nubeqa (darolutamide) and androgen deprivation therapy (ADT) has reportedly displayed positive results ...

In this article, Sandy Srinivas, MD, discusses androgen deprivation therapy as a treatment for advanced prostate cancer and examines potential avenues for future research, including androgen ...

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate ...

Androgen-deprivation therapy (ADT) is well established as the standard of care in metastatic prostate cancer (PCa) management; however, ADT has significant adverse effects (AEs) that must be ...

Recently, combined therapy with androgen deprivation therapy and androgen receptor pathway inhibitors has been recommended for metastatic hormone-sensitive prostate cancer patients.

The utilization of Xtandi (enzalutamide), compared with Zytiga (abiraterone) — both in combination with androgen deprivation therapy — in the treatment of patients with prostate cancer may be ...